{"id":732851,"date":"2021-03-31T10:00:00","date_gmt":"2021-03-31T10:00:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=2efa9e42f6397fcb3615c163fc79b38f"},"modified":"2021-03-31T10:00:00","modified_gmt":"2021-03-31T10:00:00","slug":"kamada-announces-top-line-results-from-its-phase-1-2-clinical-trial-of-its-plasma-derived-hyperimmune-globulin-igg-treatment-for-coronavirus-disease-covid-19","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/kamada-announces-top-line-results-from-its-phase-1-2-clinical-trial-of-its-plasma-derived-hyperimmune-globulin-igg-treatment-for-coronavirus-disease-covid-19\/","title":{"rendered":"Kamada Announces Top-line Results from its Phase 1\/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)"},"content":{"rendered":"<p><![CDATA[REHOVOT, Israel, March  31, 2021  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ &amp; TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1\/2 open-label, single-arm, multi-center clinical trial in Israel of the Company\u2019s anti-SARS-CoV-2 plasma-derived hyperimmune globulin (IgG) treatment for coronavirus disease (COVID-19). Interim results from this study were announced by Kamada in September 2020.]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71357],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/732851"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=732851"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/732851\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=732851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=732851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=732851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}